The Medicine Supply Chain: Who Really Controls the World’s Pharmaceuticals?

Introduction: What if One Factory Could Disrupt a Global Health System?

Imagine taking a medicine from a pharmacy shelf and tracing it backwards. The tablet may have been packaged in Germany, manufactured in Belgium, released by a pharmaceutical company in Switzerland, formulated in India, and produced from an active pharmaceutical ingredient originating in China. Before reaching the patient, it may have crossed several borders, passed through multiple regulatory systems, depended on specialised chemical intermediates, and travelled through a network of manufacturers, wholesalers, logistics providers and procurement organisations.

The modern medicine is therefore not simply a pharmaceutical product. It is the final visible point of a highly interconnected global industrial system.

This raises a strategic question for governments and healthcare systems: who actually controls the availability of medicines? The answer is more complicated than the names printed on pharmaceutical packaging. Control is distributed across manufacturers, API producers, chemical suppliers, regulators, governments, procurement systems and logistics networks. Yet the greatest vulnerabilities often appear far upstream, where patients and even healthcare providers have very little visibility.

The World Health Organization (WHO), the European Medicines Agency (EMA), the European Commission and the U.S. Food and Drug Administration (FDA) increasingly treat pharmaceutical supply resilience as an issue of public health and economic security rather than merely commercial efficiency.

From Raw Material to Pharmacy: The Journey of a Medicine

A pharmaceutical supply chain begins long before a medicine becomes a tablet, capsule, injection or infusion. In a conventional small-molecule medicine, the process can involve chemical raw materials, intermediates, the active pharmaceutical ingredient (API), excipients, formulation, manufacturing, quality control, packaging and distribution.

The API is the component responsible for producing the intended pharmacological effect. Other ingredients may provide stability, enable controlled release, improve absorption or give the medicine its physical form. Each stage can involve different companies and countries.

A pharmaceutical company therefore does not necessarily manufacture everything itself. It may purchase an API from a specialised producer, contract formulation or packaging to another company, and then distribute the finished product through wholesalers and national pharmacy networks. Regulatory authorities such as the EMA in Europe and FDA in the United States oversee different parts of this system through marketing authorisation, manufacturing standards, inspections and shortage-monitoring mechanisms.

The WHO itself maintains a prequalification system for APIs, assessing submitted data and manufacturing sites against quality and Good Manufacturing Practice requirements. Its current database contains numerous prequalified API sources from manufacturers in both Asia and other regions.

Why APIs Are Strategically Important

The API is one of the least visible but most strategically important components of the pharmaceutical system. A medicine can have a European or American brand, a sophisticated formulation and a local packaging operation while still depending on an ingredient manufactured thousands of kilometres away.

This becomes particularly important for generic medicines. Over recent decades, production of many mature, high-volume and relatively low-margin APIs has moved towards regions where manufacturing costs and industrial capacity are highly competitive. European Commission analysis has identified a strong concentration of generic API production in Asia, particularly China and India. A 2025 Commission staff working document reported that approximately 75% of API production sites relevant to its analysis were located outside the EU, with India and China among the most important locations; for around 21% of the APIs examined, there was no production within the EU at all.

This does not mean that China or India “control” global pharmaceuticals in a simple sense. The pharmaceutical industry remains highly diversified, and the United States, Europe, Japan, Switzerland, South Korea and other economies retain major capabilities. But it does mean that certain parts of the supply chain have become geographically concentrated, creating strategic dependencies.

India itself is a major producer of generic medicines but also relies on imported pharmaceutical inputs, including APIs and intermediates from China. This creates an important distinction: a medicine manufactured in India may still contain upstream dependencies originating elsewhere.

The Asian Manufacturing Network

China and India occupy particularly important positions in the global pharmaceutical ecosystem, but for different reasons. China has developed extensive capabilities in chemical manufacturing, intermediates and APIs, while India has become one of the world's leading manufacturers and exporters of generic medicines.

The relationship between the two countries illustrates how supply-chain dependency can exist even between major pharmaceutical powers. Historical WHO analysis has documented India's substantial reliance on Chinese APIs for its generic pharmaceutical sector.

For Europe, the issue is not simply the amount of medicine purchased from Asia. The deeper question is where the underlying production capacity resides. A European pharmaceutical manufacturer may have multiple suppliers on paper while those suppliers themselves depend on the same upstream chemical producer.

This creates what can be called hidden concentration. Three apparently independent pharmaceutical companies may ultimately depend upon one common API producer, chemical intermediate, raw-material supplier or manufacturing region.

Consequently, counting suppliers alone does not necessarily measure resilience. The critical question is whether those suppliers are genuinely independent.

Geopolitics Enters the Pharmacy

The pharmaceutical supply chain has consequently become part of economic security and geopolitical strategy.

Pandemics, export restrictions, trade disputes, sanctions, wars, energy disruptions and transport interruptions can all affect pharmaceutical availability. During periods of crisis, governments may prioritise domestic needs or restrict exports of strategically important products. Even when governments do not deliberately restrict medicines, disruptions in energy, shipping, chemicals, labour or industrial infrastructure can propagate through the supply chain.

The COVID-19 pandemic demonstrated how rapidly global production networks could become stressed. More recently, geopolitical tensions and concerns about economic dependence have encouraged governments to reconsider whether the cheapest global supply chain is necessarily the safest.

For the European Union, this has become a central policy issue. The European Commission proposed the Critical Medicines Act in March 2025, explicitly aiming to improve availability, diversify supply chains and strengthen production capacity within Europe. In May 2026, the European Parliament and Council reached a provisional agreement that included resilience requirements in public procurement, incentives for EU-based production, collaborative procurement and measures concerning contingency stocks. As of August 2026, the agreement still requires formal adoption.

The significance is considerable: medicine procurement is increasingly being treated as an instrument of industrial policy.

What Happens When One Link Breaks?

A shortage does not necessarily require a global catastrophe. Sometimes one relatively small failure is sufficient.

A manufacturing site may experience a quality problem. A chemical supplier may have a production interruption. A shipping route may become unavailable. Demand may suddenly increase. A company may decide that an older medicine is no longer commercially attractive.

The FDA identifies manufacturing and quality problems as major causes of drug shortages, alongside production delays, raw-material constraints, unexpected increases in demand and discontinuation of products. Older sterile injectable medicines can be particularly vulnerable because relatively few manufacturers may possess the specialised capacity required to produce them.

The consequences can propagate through the system.

One factory stops, One API becomes scarce, Several manufacturers reduce production, Wholesalers receive fewer units, Hospitals begin rationing inventory, Pharmacies experience shortages, Patients encounter a problem that began months earlier and thousands of kilometres away.

This time lag is one reason pharmaceutical resilience is difficult. By the time a shortage becomes visible to a patient, the underlying disruption may already be deeply embedded in the production system.

The EMA's experience reinforces this point. In 2025, its shortage-monitoring network received 70 notifications of critical shortages, while the European Shortages Monitoring Platform became fully operational to centralise information about supply and demand. The EMA also coordinated six voluntary solidarity procedures between EU Member States during critical shortages.

The Rise of Regional Pharmaceutical Production

The emerging response is not necessarily complete self-sufficiency. Rebuilding every pharmaceutical capability inside every country would be economically unrealistic and could itself create inefficiencies.

The more practical objective is strategic diversification.

This may mean maintaining multiple API suppliers across different regions, creating additional manufacturing capacity for critical medicines, developing regional production of essential intermediates, maintaining appropriate reserves and improving transparency across the supply chain.

The EU's Critical Medicines Act reflects this approach. Its provisional agreement supports EU-based strategic projects, resilience-oriented procurement and collaborative purchasing between Member States. The objective is not to eliminate international trade but to reduce dangerous concentrations of dependency.

The same principle is visible in EMA policy. Its Medicines Shortages Steering Group has recommended measures including diversification of suppliers, additional manufacturing sites, improved forecasting and, where appropriate, stockpiling for medicines identified as vulnerable.

Regional production therefore represents a shift from efficiency-first globalisation toward resilience-oriented globalisation.

Who Really Controls the World's Pharmaceuticals?

There is no single institution, corporation or country that controls the world's pharmaceutical supply chain. Instead, control is distributed across a complex architecture.

Pharmaceutical companies control product portfolios, manufacturing decisions and investment. API and chemical manufacturers control critical upstream production capacity. Governments and regulators determine which products can enter markets and increasingly influence procurement and resilience requirements. Wholesalers and logistics companies determine how medicines move through distribution networks. Healthcare systems and procurement agencies influence demand and pricing. Finally, geopolitical actors can influence the operating environment through trade policy, export controls and industrial strategy.

The real source of power is therefore not simply ownership. It is control over indispensable capacity.

A company that produces a commodity API used by dozens of manufacturers may have little public visibility but enormous strategic importance. A country that hosts a concentrated manufacturing cluster may possess significant leverage even without producing the final branded medicines consumed elsewhere.

The Next Pharmaceutical Era: Resilience as a Strategic Asset

The pharmaceutical industry is entering a period in which supply-chain architecture will become almost as important as scientific innovation.

The question facing governments is no longer simply whether a medicine can be invented, approved and sold. It is whether the medicine can remain manufacturable, affordable and accessible under adverse conditions.

The European approach illustrates this transition. The Union now maintains a list of critical medicines, conducts vulnerability assessments and is developing industrial and procurement mechanisms to reduce supply risks.

The likely future is therefore not a retreat from globalisation but a redesign of it. Pharmaceutical production will remain international, but strategic medicines are increasingly likely to be supported by multiple production regions, greater transparency, stronger inventories, diversified suppliers and regional manufacturing capacity.

The tablet on the pharmacy shelf may look simple. Its supply chain is anything but.

And perhaps the most important lesson is this: a resilient healthcare system does not begin at the hospital or pharmacy. It begins much earlier, at the factory, the chemical plant, the API producer and the geopolitical relationships connecting them.